Metformin and rosiglitazone are useful in AN characterized by IR; they reduce glucose production by increasing peripheral insulin responsiveness, reducing hyperinsulinemia, body weight, and fat mass and improving insulin sensitivity in peripheral muscles. Here, INS is linked to hyperinsulinism.